Podcasts about Prospective

Antoine Bordes est Chief Scientist de Helsing, une entreprise européenne spécialisée dans les applications de l'intelligence artificielle au secteur de la défense.Expert de renommée mondiale, il a passé neuf années à bâtir le laboratoire de recherche en intelligence artificielle de Meta, dont les trois dernières en tant que co-directeur.Dans l'entretien à suivre, Antoine explore plusieurs pistes pour permettre à l'Europe de préserver sa souveraineté et ses principes démocratiques.À travers des notions clés, telles que l'autonomie stratégique et le “découragement” algorithmique, il s'interroge à voix haute sur ce que signifie protéger des démocraties dans un monde de drones, de techniques de brouillage inédites et de cycles technologiques accélérés.Entretien enregistré le 13 février 2026no(s) limit(es) | une production Logarythm | disponible sur L'Atelier des FutursMontage : Denis Démocrate Marouzé NicolasHébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

In our second week, we cover most of the 'marks of a healthy church' form 9Marks ministries. You can watch this message here.

Grab our breakdown of the 5 Low-Cost Businesses That Make $1 Million: https://www.franchiseempire.com/lowcost?utm_source=TJfeb212026Is owning a tool truck actually a smart business in 2026? In this video, I break down how the Snap-on Tools business model works, how much it costs to start, what franchisees are making, and the real pros and cons of a mobile tool business. This is not your typical franchise. There are no royalties, no marketing fees, and they even offer in-house financing. But there's a catch: when you sell physical products, your margins are very different than service businesses. If you're looking for a mobile business opportunity under $250K-$500K and want to know whether this is a real path to replacing your income, this breakdown will help you think clearly before making a move. Comment below - would you run a tool truck?------------------Considering Investing In A Franchise?

Budget Blinds might sound boring, but this home service franchise is quietly generating serious revenue. In this video, we break down how much it costs to start a Budget Blinds franchise, what franchisees are actually making, how the royalty model is changing in 2026, and whether this is truly a good investment. I've personally looked into buying a resale myself, and I know multiple owners in the system. If you're looking for a low-cost franchise that isn't flashy but has real numbers behind it, this breakdown will help you decide if this “boring” business could actually build wealth. Comment below if you would ever own a business like this. ---------------------------------------------------------------------------------------Free Resources to Get You Started!Download our list of 42 High Performing (and profitable) Franchises: https://www.franchiseempire.com/42hpf?utm_source=TJfeb222026Download our FREE StarterKit: The Zero to Profitable Franchise in Less Than 12 Months Guide:  https://www.franchiseempire.com/o-ztpf-guide?utm_source=TJfeb222026

Valérie Mussard explique comment elle anticipe l'impact de l'IA. Elle revient également sur la récente publication de son groupe consacrée à la mesure de l'impact social et sur son influence sur les politiques RH internes. Enfin, elle souligne en quoi le dialogue social constitue un véritable levier de transformation.Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

À l'occasion du sommet Choose France, le 13 mai 2024, Emmanuel Macron avec sa phrase “plug, baby, plug”, invitait des entreprises comme Microsoft et Amazon à implanter des data centers en France pour profiter d'une énergie bas-carbone. Mais sait-on ce qu'est vraiment un datacenter, ses conséquences environnementales, ses futurs impacts… sur notre futur. Pour répondre à nos questions, au micro de Techologie, Cécile Diguet, experte en architecture, design urbain et l'impact des datacenters sur son territoire, coautrice avec Fanny Lopez du livre Sous le feu numérique, Spatialités et énergies des data centers, paru en 2023 aux éditions MétisPresses, coautrice d'un rapport pour l'Ademe : Prospective d'évolution des consommations des centres de données en France de 2024 à 2060. En savoir plus : Prospective d'évolution des consommations des data centers à court, moyen et long terme de 2024 à 2060 https://librairie.ademe.fr/energies/8910-10774-prospective-d-evolution-des-consommations-des-data-centers-a-court-moyen-et-long-terme-de-2024-a-2060.html#/44-type_de_produit-format_electronique

Seth and Sean take a look at what's likely to be the Texans' offense at this point, assess which parts need an upgrade, and see what Daniel Jeremiah has the Texans doing in the 1st round in the daily Mock Draft Injection.

Seth and Sean dive into what would appear to be the Texans' prospective starting offense at this point and assess which positions are most in need of an upgrade.

Episode 179 hosts Faye Holland and James Parton sit down with Irina Barbina (CEO) and Matthew Griffiths (CTO) to unpick how Concr is using predictive modelling and digital twins to transform cancer drug development.Cancer data is fragmented. Clinical trials, pre-clinical research, and real-world patient data exist in silos. There's no unified way to predict how individual patients will respond to specific therapies, until now.Concr's technology borrows from astrophysics, specifically, how scientists model dark matter using gravitational lensing. The parallel is striking: Astrophysicists can't directly observe dark matter, so they build complex simulations to infer its distribution. Concr can't directly know why a drug worked for a patient, so they build digital twin simulations to predict outcomes.Key innovations:· Bayesian inference at scale to handle messy, incomplete cancer data· Hierarchical modelling that learns from shared biology across cancer types· 94% prediction accuracy on retrospective clinical trial data· Prospective validation underway with NHS partners and pharma companiesConcr dramatically reduces the cost and complexity of clinical trials. This episode brilliantly illustrates why Cambridge is a global innovation hub. It's not just about brilliant science, it's about brilliant people from different disciplines colliding, recognising patterns, and building companies that matter. Hosted on Acast. See acast.com/privacy for more information.

In this 20-minute episode of RISE Radio, Editorial Director Ilene MacDonald sits down with Dr. Matt Lambert, the former chief medical officer at Reveleer, to unpack the rapidly evolving landscape of Medicare Advantage risk adjustment. Together, they discuss the implications of the 2027 Advance Notice, new OIG compliance guidance, and the industry's shift toward encounter-based, prospective risk adjustment. Dr. Lambert explains how hybrid AI—combining generative AI with long‑standing clinical rules—can improve accuracy, reduce false positives, and streamline workflows for providers, payers, and risk adjustment teams. He also shares practical strategies for organizations beginning this transition, emphasizing partnership, user‑friendly workflows, and technology that meets clinicians at the point of care.About Matt Lambert, M.D. Dr. Matt Lambert, is the former chief medical officer at Reveleer and a leader in health care innovation, blending clinical expertise with technology, policy, and payment strategies. He previously served as CMO of Curation Health (acquired by Reveleer in 2024) and led digital transformation at Clinovations and The Advisory Board. He has been CMIO for New York City Health + Hospitals, RWJ Barnabas, and Johns Hopkins, overseeing Epic and Cerner implementations. An emergency medicine physician for 20+ years, he authored two books on health care reform. He earned his MD from Marshall University and trained at West Virginia University. About ReveleerReveleer, a health care software and services company, uses machine learning and intelligent automation technology to empower health plans control over their quality improvement, risk adjustment, and member management programs. With one transformative solution, Reveleer allows plans to independently execute and manage provider outreach and data retrieval, coding, abstraction, member management, and reporting. Reveleer leverages proprietary technology, robust data sets, and subject matter expertise, so health plans can execute programs that deliver value and improved outcomes. Click here for Reveleer's Guide to AI in Value-Based Care.

Five articles from the February 2026 issue summarized in five minutes, with the addition of a brief editorial commentary. The 5-in-5 feature is designed to give readers an overview of articles that may pique their interest and encourage more detailed reading. It may also be used by busy readers who would prefer a brief audio summary in order to select the articles they want to read in full. The featured articles this month are: Intraoperative Zoledronic Acid for Arthroscopic Rotator Cuff Repair: Short-Term Results From a Prospective, Randomized, Placebo-Controlled Phase II Trial Dermal Allograft Augmentation for Open Gluteus Medius Repair: A Case Series at 2-Year Follow-up Prediction of Contralateral Patellar Instability After Ipsilateral Medial Patellofemoral Ligament Reconstruction Arthroscopic Primary Labral Reconstruction in the Hip: Minimum 10-Year Outcomes With a Nested Propensity-Matched Control Using a Residual Pivot Shift as the Indication to Perform a Lateral Extra-articular Tenodesis During ACL Reconstruction Using Autologous Hamstring Grafts Is Associated With Improved Surgical Outcomes: A Retrospective Review of 4755 Cases Click here to read the articles.

What does Scripture teach about church membership and church discipline? Does the New Testament assume believers should be members of a local church? You can watch this message here.

⚠️ Découvrez du contenu EXCLUSIF (pas sur la chaîne) ⚠️ ⇒ https://the-flares.com/y/bonus/ ⬇️⬇️⬇️ Infos complémentaires : sources, références, liens... ⬇️⬇️⬇️ Le contenu vous intéresse ? Abonnez-vous et cliquez sur la

Commentary by Dr.  Jian'an Wang.

Unexplained infertility, PMS, and low progesterone are often dismissed when labs fall “within range.” In this episode, Dr. Brendan McCarthy explains why prolactin may be the missing piece. Learn how mildly elevated prolactin can suppress ovulation, lower progesterone, and impact fertility—even when labs appear normal. We also discuss common causes, symptoms, the role of stress and medications, and why diet (including gluten sensitivity) may matter. This episode focuses on precision medicine, not fear—helping you understand what standard reference ranges often miss. Citations: Research — Prolactin and Breast Cancer Risk Below are key epidemiologic and review papers that inform the discussion in this episode regarding prolactin and breast biology. These studies look at associations, not simple cause-and-effect relationships, and help explain why prolactin shows up in breast health conversations. Meta-analysis: circulating prolactin and breast cancer risk Wang M, et al. (2016). Plasma prolactin and breast cancer risk: a meta-analysis. Cancer Causes & Control. This meta-analysis pooled data from multiple observational studies comparing women with higher versus lower circulating prolactin levels. Across studies, higher prolactin levels were associated with a modest but statistically significant increase in breast cancer risk. The association was most evident in postmenopausal women and in hormone-receptor–positive tumors. This helps explain why prolactin is considered a relevant growth signal in breast tissue rather than just a “lactation hormone.” Systematic review and meta-analysis: prolactin levels across breast cancer cohorts Aranha AF, et al. (2022). Impact of prolactin levels in breast cancer: a systematic review and meta-analysis. Endocrine-Related Cancer. This more recent systematic review and meta-analysis evaluated circulating prolactin levels across breast cancer populations and control groups. Elevated prolactin levels were associated with higher breast cancer occurrence, with stronger associations seen in invasive cancers and hormone-receptor–positive disease. This paper adds weight to the idea that prolactin participates in breast biology in ways that matter clinically, even outside of pregnancy and breastfeeding. Prospective cohort studies: prolactin measured before diagnosis Tworoger SS, et al. (2004; 2006). Prospective analyses from large cohorts including the Nurses' Health Study. In these studies, prolactin was measured years before any breast cancer diagnosis. Women with higher prolactin levels had a higher likelihood of developing breast cancer later, particularly estrogen-receptor–positive tumors in postmenopausal women. Because prolactin was measured before cancer developed, these studies help clarify timing and reduce the concern that elevated prolactin is simply a consequence of disease. Mechanistic context (supportive background) Experimental and translational studies show that prolactin receptor signaling influences mammary epithelial cell growth, differentiation, and interaction with estrogen signaling pathways. This provides a biologic backdrop for why epidemiologic associations between prolactin and breast cancer risk keep appearing across different study designs. How to read this as a clinician or patient These data do not mean prolactin “causes” breast cancer in a simple or deterministic way. What they do show is that prolactin is an active hormone in breast tissue, and chronically higher levels are consistently associated with changes in breast risk profiles across large populations. That's why prolactin deserves attention in conversations about fertility, breast symptoms, and long-term hormonal signaling—not fear, and not dismissal.    Dr. Brendan McCarthy is the founder and Chief Medical Officer of Protea Medical Center in Arizona. With over two decades of experience, he's helped thousands of patients navigate hormonal imbalances using bioidentical HRT, nutrition, and root-cause medicine. He's also taught and mentored other physicians on integrative approaches to hormone therapy, weight loss, fertility, and more. If you're ready to take your health seriously, this podcast is a great place to start.  

Dr. Monty Pal and Dr. Atul Batra discuss the PLANeT study from India, which evaluated low-dose pembrolizumab in addition to neoadjuvant chemotherapy for triple-negative breast cancer, and its place among a growing body of international research on improving efficacy while reducing costs and toxicity with lower doses of immunotherapy. TRANSCRIPT Dr. Monty Pal: Hello and welcome to the ASCO Daily News Podcast. I'm your host, Dr. Monty Pal. I'm a medical oncologist, professor, and vice chair of academic affairs at the City of Hope Comprehensive Cancer Center, Los Angeles. My guest today, I think, is going to be a really riveting one. It's Dr. Atul Batra, who is an additional professor of medical oncology at the All India Institute of Medical Sciences, or AIIMS, in New Delhi. And he's also the senior author of the PLANeT study. It's a very compelling study that evaluated low-dose pembrolizumab in addition to neoadjuvant chemotherapy for triple-negative breast cancer. And it's really a big part of a growing body of research that's showing balanced efficacy when we use lower doses of immunotherapy instead of standard doses to reduce cost, as well as potentially toxicity. I think this has huge implications for our global audience, and I'm so thrilled to have you on the podcast today, Dr. Atul Batra, welcome. Dr. Atul Batra: Thank you, Dr. Pal. Dr. Monty Pal: And we'll just take it with first names from here since we're both friends. I have to give the audience some context. Atul, I had the great honor of visiting AIIMS New Delhi. For those that don't know, this is really, you know, the Harvard Medical School of India. It's the most competitive institution for medical training. And on the back end of that, there's also incredible resources when it comes to clinical trials and infrastructure. I just wanted to have you give the audience sort of a scope of the types of trials that you've been able to do at AIIMS New Delhi. Dr. Atul Batra: Thank you, Monty. So, I work at the All India Institute of Medical Sciences, and we had the honor and pleasure of having Monty here this month. And people are still in awe of his lectures that he delivered there. Coming back to our institute, so it's kind of a medical college. It's one of the oldest ones, it was built in 1956. We are lucky enough that we get the best of the residents and fellows because they have to go through an exam, a competitive exam, and mostly it's them who come to us and we're able to do some good work out here. Regarding the trials that we have conducted, we do conduct some investigator-initiated studies, and we try to answer the questions where we can help our own patients. Like, for example, this PLANeT study. Every other patient in the clinic was almost not able to afford Keytruda at the full dose, pembrolizumab, and we had a lot of evidence creeping in that a lower dose might be helpful. And that's how we planned this study. Before that, there are certain cancers that are peculiar to India, like gallbladder cancer, head and neck cancers. These are much more common in India as compared to the U.S., and there are some good studies that have been conducted from our own institute by our senior colleagues which have been presented at ASCO and published in the JCO. We also did the capecitabine hand-foot syndrome study that was known as the D-ToRCH study: 1% diclofenac gel that became the standard of care to prevent hand-foot syndrome.  So, that's kind of a brief overview of investigator-initiated studies. India is slowly and steadily becoming a partner of the global registration trials. And it's more recently, the last five years or so, we have seen that the number of phase 2 and phase 3 trials are increasing and we are able to offer now these trials as well to our patients. Dr. Monty Pal: That was a terrific overview. I just want to highlight for the audience, as we go through some of your discussions today around specific trials, the speed at which this can be done. Just for context, for me to accrue a clinical trial of 30 patients – I think many people have probably come across some of the work that I've done in the microbiome space – at a single institution, 30 patients, right, takes me about a year and a half, two years. We're going to go through some trials today where Dr. Batra and his team have actually, in fact, accrued close to 200 patients over a span of just a year, which is just remarkable by, I would say, any American standard. So, I see a real need for partnership and Atul, I'll kind of get back to that at the end. But without further ado, the focus of this podcast today, I think, is really this terrific presentation you gave in an oral session at ESMO and subsequently published in Annals of Oncology related to the PLANeT study. Would you give the listeners some context around what the study entailed and population and so forth? Dr. Atul Batra: So, we know the KEYNOTE-522 became the standard of care for triple-negative breast cancer, where Keytruda, when added at 200 mg, the standard dose every three weeks with neoadjuvant, increases the pCR from around 51% to 64% by a magnitude of around 13%. However, in India and other low-middle income countries, less than 5% of the patients actually have access to this dose of pembrolizumab. So, our standard of care was actually just chemotherapy till now. And this kind of led us to design this trial. There are data that come from previous trials conducted in India, from the Tata Memorial, done in head and neck space, some other studies done in Hodgkin's lymphoma, that a much lower dose, probably around one-tenth of the dose, works well in these cancers. So, that's where we designed the PLANeT study, where we gave the standard neoadjuvant chemotherapy in the control arm, and in the experimental arm we added 50 mg of pembrolizumab. This was given every six weeks for three doses. So, that's a total of 150 mg over the neoadjuvant period as compared to 1,600 mg that was given in the KEYNOTE-522 study. So, this was almost one-tenth of the study. Dr. Monty Pal: So, a tenth of the dose, which is just remarkable. I mean, that's just such an interesting concept. Dr. Atul Batra: And the results, when we – the primary outcome, this was a phase 2 study. We just wanted to see, is there a signal of activity? And to even our surprise, when we looked at the pathological complete response rates, in the control arm this was 40.5%, and in the experimental arm this was 53.8%. So, a difference came to around 13.3%; it was numerically, I mean, so much similar to what KEYNOTE-522 had with just these many doses. So, this was around 160 patients randomized over one year. We could randomize them in one year because of the load that we see. And the primary endpoint was met, and we could see that the path complete response did show a remarkable increase. We are still following these patients to see whether there is a difference in event-free survival at a longer follow-up. Until now, it's a small follow-up, so the number of events absolute, are different: four events in the experimental arm and 11 events in the control arm. So, we are seeing some signal even in this much short follow-up period as well. But we need to see more of what happens in the longer term. Dr. Monty Pal: That's so impressive. I wonder, with this lower dose, do you attenuate toxicity at all as far as you can gather? Dr. Atul Batra: So, although we shouldn't be doing kind of cross-trial comparisons, but if you look at thyroid dysfunction, we saw that around 10% of our patients had this thyroid dysfunction. This was compared to 15% in the KEYNOTE-522, that was a larger sample size though. But we're seeing that all the toxicities are somewhat less as compared to those in the standard dose. So, the exposure is less, but I mean, I can't really commit definitely on this. For this we would need much more data to say this with more confidence. Dr. Monty Pal: Yeah. I'm going to ask you a really tough question to follow up, and this is probably something that's on everyone's mind after reading a study like this. Is this something that is disease-specific that needs to be replicated across other histologies? The reason I ask this is, you know, you think about paradigms like, for instance, in the States we're toying between intravenous versus subcutaneous delivery of checkpoint inhibitors, and we have studies focused in specific histologies that might justify use across all histologies. With this particular phenomenon, do you think we need to do dedicated studies in renal cell or in colon cancer and other places where, you know, in selected settings we might use checkpoint inhibitors and then decide whether or not there's this dose equivalence, if you will? Dr. Atul Batra: That's a real tough one, though. But I'm happy to share that there are several ongoing studies within India currently. At our institute, my colleagues are leading studies in lung cancer space, cervical cancer. There was already a publication from Tata Memorial Hospital in head and neck cancers and we see that the signal has been consistent throughout. Regarding renal cancer, there was one study that was presented for sure at ASCO from CMC Vellore, that's again a center in South India. That was in RCC at a much lower dose. And for patients who cannot take the full dose, we actually are offering lower dose nivolumab in such patients and we are seeing responses. I mean, we haven't done those randomized trials again because the numbers are much lower in kidney cancers, we know. We could do this trial in triple-negative ones because we had support and we had numbers to conduct this trial. But I'm sure this should be a class effect. I mean, when we can get tumor-agnostic approvals, then some real-world data has come up in almost all tumors, we have seen that consistent effect across tumors. And as we speak of today, I'm also delighted to share that in India, yesterday, we had the first biosimilar of nivolumab and that's now available at a much, much lower price than the original patent product. There was a long ongoing lawsuit that was there, that's over now, and from yesterday onwards, I'm so happy to share here that we would have the first biosimilar of nivolumab that's available. That's going to bring the cost to almost like one-tenth already. Dr. Monty Pal: Wow. That's huge.  I'm going to be very selfish here for a second and focus on a study that is in the renal cell space that your group has done. You know, when it came out, I was really sort of intrigued by this study as well and it reflects sort of a different capability, I think, of AIIMS New Delhi, and that's in the, what I'm going to call, biomarker space. This, for the audience, was a prospective effort to characterize germline variants in patients with advanced kidney cancer. And it's something that we talk about a lot in the kidney cancer literature, whether or not we're missing a lot of these so-called hereditary patterns of RCC. Can you tell us a little bit about that study too? Dr. Atul Batra: Yeah, so that was led by one of our fellows, Chitrakshi Nagpal, and she's just completed her fellowship. And two years back we published that. So, that was done in almost 160 consecutive patients that we recruited over the span of just one year and we saw, apart from the common known mutations in RCC, that was around 5% or so, but a lot of other mutations were also seen that we don't generally see in kidney cancers and we see in other cancers like BRCA1, BRCA2 and others. We are still, I mean, doing those analyses to see whether we get more things out of there in the somatic: is there a loss of heterozygosity or was it just present and in there? Dr. Monty Pal: I thought it was a terrific study and again, I was just so blown away at the pace. I mean, as I look at 140 patients accrued over a span of one year, this is something that would take us perhaps three times as long at City of Hope, and that's with a very sort of, what I consider to be large and dedicated kidney cancer program. So, it really underscores, I think, the need for collaboration. And ever since I came back from my visit to you at AIIMS Delhi, I think I've just been sort of transformed in the sense of trying to think of better ways for us to collaborate. One tangible thing that I'm going to get cracking on is seeing whether or not perhaps we can form some partnerships through SWOG or what we call the NCTN, the National Clinical Trials Network here within the U.S. Talk to me about collaboration. I mean, you've been really terrific at this. How do you sort of envision collaboration enhancing the global landscape of oncology? Dr. Atul Batra: That's really amazing, Monty. That's what we need. We have the infrastructure, we have the manpower, we have patients. I mean, these are all high-volume centers. Unfortunately, we are a little less in numbers, so we are more clinically occupied as well. So, sometimes it's kind of tougher, but again, when it comes to helping out the patients, global collaboration, we need to kind of take you guys along with us and have our patients finish trials earlier. This is a win-win situation for patients, one, because they also get exposure or an option to participate in the clinical trials, and second, we can answer all these scientific questions that we have at a much faster pace. All those things can be done within a much shorter span of time for sure. We are so happy to hear that, and with open hands we are ready to collaborate for all these efforts. Dr. Monty Pal: That's awesome. You know, I came back thinking, gosh, this would be so ideal for some of these rare subtypes of kidney cancer. Prospective clinical trials that I'm running in that space where really we're threatened with closure all the time. And if we just sort of extended a hand to, you know, our partners in India and other countries, you know, I'm sure we could get this research done in a meaningful way and that's got to be a win for patients. Atul, I had such a terrific time chatting with you today. I'm looking forward to seeing lots more productivity from your group there. By the way, for our viewership here, take a look and see what AIIMS New Delhi is doing under the leadership of Dr. Batra and others. It is just a real powerhouse and I think that after doing so, you'll be enticed to collaborate as well.  I'm hoping this is the first of many times that we have you on the podcast. Thank you so much for joining. Dr. Atul Batra: Thank you so much for having me here, Monty. It was a pleasure as always speaking to you. And thank you again. Dr. Monty Pal: You got it.  Well, and thanks to our listeners. I encourage you to check out Dr. Batra's paper. We'll actually have a link to the study in the transcript of this episode.  Finally, if you value the insights that you heard today on the ASCO Daily News Podcast, please rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. More on today's speakers:     Dr. Monty Pal   @montypal Dr. Atul Batra @batraatulonc Follow ASCO on social media:          ASCO on X    ASCO on Bluesky         ASCO on Facebook          ASCO on LinkedIn          Disclosures:       Dr. Monty Pal:      Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview     Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical     Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis     Dr. Atul Batra: Stock and Other Ownership Interests: Zydus Pharmaceuticals, Glenmark, Caplin Point Laboratories, Laurus Research Funding: AstraZeneca, Astellas Pharma, Alkem Laboratories

Monday, February 02, 2026 The Dominant Duo – Total Dominance Hour -Al has an announcement, Thunder reclaim the narrative, SGA B2B MVP talk, Giannis trade in June, OU Basketball with prospective arena and more. Follow the Sports Animal on Facebook, Instagram and X PLUS Jim Traber on Instagram, Berry Tramel on X and Dean Blevins on X Follow Tony Z on Instagram and Facebook Listen to past episodes HERE! Follow Total Dominance Podcasts on Apple, Google and SpotifySee omnystudio.com/listener for privacy information.

Download our list of 42 High Performing (and profitable) Franchises: https://www.franchiseempire.com/42hpf?utm_source=podcastEveryone wants passive income, but most people have no idea what it really takes to make a semi-absentee franchise work. In this episode, we break down exactly how to set up your franchise to succeed if you can't be full-time from day one. You'll hear real strategies from our own team, the mistakes we've seen others make, and how to think like a top-performing owner.------------------Considering Investing In A Franchise?

What's it like to have the responsibility of discerning whether a man or woman would be a healthy and suitable priests or religious?Dr. Anthony Isacco shares his humble insights into the quietly holy work of psychological assessments in the process of discernment.Support the showThank you for listening, and a very special thank you to our community of supporters! Visit us online at thiswholelifepodcast.com, and send us an email with your thoughts, questions, or ideas.Follow us on Instagram & FacebookInterested in more faith-filled mental health resources? Check out the Martin Center for IntegrationMusic: "You're Not Alone" by Marie Miller. Used with permission.

"The United States does not have a national cancer registry. We have a bunch of state registries. Some of those registries do collaborate and share information, but the issue is the registries that do exist typically do not report cancer by occupation. So, we cannot get our arms around the potential work-relatedness of the health outcome given the current way the state registries collect information. What we're trying to set up, is a way to make what is currently an invisible risk, visible," ONS member Melissa McDiarmid, MD, MPH, DABT, professor of medicine and epidemiology and public health director of the division of occupational and environmental medicine at the University of Maryland School of Medicine in Baltimore, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about the University of Maryland School of Medicine Hazardous Drug Safety Center Exposure Registry. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.75 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by January 23, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge in the incidence of hazardous drug exposure and the tracking and reporting of healthcare worker exposures. Episode Notes  Complete this evaluation for free NCPD. University of Maryland School of Medicine Hazardous Drug Safety Center Exposure Registry information sheet ONS Podcast™ episodes: Episode 330: Stay Up to Date on Safe Handling of Hazardous Drugs Episode 308: Hazardous Drugs and Hazardous Waste: Personal, Patient, and Environmental Safety Episode 209: Updates in Chemo PPE and Safe Handling ONS Voice articles: Hazardous Drug Surface Contamination Prevails, Despite More Diligent PPE National Hazardous Drug Exposure Registry Safeguards Oncology Professionals NIOSH Releases Its 2024 List of Hazardous Drugs Safe Handling—We've Come a Long Way, Baby! Strategies to Promote Safe Medication Administration Practices Surfaces in Patient Bathrooms Often Contaminated With HDs, Despite Use of Plastic-Backed Pads ONS books: Safe Handling of Hazardous Drugs (fourth edition) Safe Handling of Hazardous Drugs Quick Guide™ ONS course: Safe Handling Basics Clinical Journal of Oncology Nursing articles: Hazardous Drug Exposure: Case Report Analysis From a Prospective, Multisite Study of Oncology Nurses' Exposure in Ambulatory Settings Personal Protective Equipment Use and Surface Contamination With Antineoplastic Drugs: The Impact of the COVID-19 Pandemic Sequential Wipe Testing for Hazardous Drugs: A Quality Improvement Project The Use of Plastic-Backed Pads to Reduce Hazardous Drug Contamination Oncology Nursing Forum articles: Ensuring Healthcare Worker Safety When Handling Hazardous Drugs Factors Influencing Nurses' Use of Hazardous Drug Safe Handling Precautions Other ONS resources: ONS Safe Handling of Hazardous Drugs Quick Guide Introduction to Safe Handling Huddle Card Safe Handling of Hazardous Drugs Learning Library Hematology/Oncology Pharmacy Association (HOPA) course: Safe Handling of Hazardous Drugs National Institute for Occupational Safety and Health (NIOSH) List of Hazardous Drugs in Healthcare Settings, 2024 To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "We thought that in order to answer some of the unclear questions about health risk, we would set up an exposure registry, in this case, for oncology personnel who handle the drugs. This would then create a cohort that we could ask questions to. For example, we could try to characterize whether there is a cancer excess in this group. Or characterize the reproductive abnormalities in excess that people are experiencing." TS 6:21 "It's sort of counterintuitive that the healthcare industry, whose mission itself is care of the sick, is a high-hazard industry. We typically think about the risk as being from infectious diseases, and certainly we've all lived in our practice lifetime through some examples of that. Even before COVID-19, some of us were doing preparation for Ebola and that sort of thing. So, we're kind of used to that. But the hazards that you kind of grew up with, we've routinized or normalized handling group one, human carcinogens, which a number of these drugs are—it's just something we do every day. Well, it is, but we have to do it with respect and with care every day. And I think sometimes in that routineness of it, we have sort of lost sight of the vigilance that we need to maintain." TS 11:19 "It's very easy in the life cycle of a drug in an organization to do something that doesn't just impact you, but unknowingly, you've contaminated a surface for somebody who comes behind you. Who maybe doesn't have plastic protective equipment on because something that got contaminated shouldn't have been contaminated in the first place. If we could all be thinking of it as more of a team sport, especially in terms of safe handling, that our disposition and drug handling affects not just us and our health, but those of our colleagues." TS 24:47 "For the job history pieces, we ask what year you started, what year you stopped, and we ask about estimations of handling. So we'll be able to come up with either a duration or some kind of metric for the intensity and duration of your handling history, which will then permit us to sort the population who completed the survey into sort of low, medium, high. And we'll see whether the health outcomes that are being reported are influenced by that drug handling history." TS 27:45 "The idea that we aren't exposed to the same therapeutic dose we give to our patients is absolutely true. However, the dosing schedule to them versus us is very different, and we are exposed frequently, if not daily, to very small concentrations. They don't reach a cytotoxic dose necessarily, but we do know from a lot of studies that either ourselves or our colleagues are taking up drug from contaminated work environments. And you've probably seen there is an awful lot of intermediate evidence looking at genotoxic insult in pharmacists and nurses who handle the drugs. So clearly we're showing uptake and we're showing that there are biologically plausible, concerning measures that are taking place in us. So, I think that we need to come back and circle around the idea that we need to have deep respect for the toxicity of these agents." TS 35:03

Jean-François Poulin présente une entrevue avec Éric Brangier consacrée à l'ergonomie prospective. Une approche qui vise à anticiper les usages et les besoins futurs, plutôt que de répondre uniquement à des problèmes immédiats. Une réflexion sur le rôle de l'UX pour remettre l'humain au centre des choix d'innovation, sur des horizons de plusieurs années.

[Audio section from Video on 01-21-2026]: Glenn Jessome, President & CEO of Silver Tiger Metals (TSX.V:SLVR) (OTCQX:SLVTF), joins me for a special video segment which visually unpacks the key metrics, maps, and forward-looking plan for the Preliminary Economic Assessment (PEA) for the underground mining second phase of the El Tigre Project.   We also review what the combined El Tigre Silver-Gold Project in Sonora, Mexico looks like on a valuation standpoint, when one sees the first phase surface mining stockwork zone in tandem with the underground second phase.     The bolt-on PEA is centered on the underground mining economics of the high-grade El Tigre, Sulphide, Black Shale and Seitz Kelly zones. The PEA mine design can be constructed independently of the Stockwork Zone development and is focused on the underground Mineral Resource. Prospective areas exist outside of the areas defined by the PEA and PFS with the historic “El Tigre North Mine” Mineral Resource located 700 metres to the North.   Highlights of the PEA , with a base case silver price of $38/oz and gold price of $3,200/oz are as follows (all figures in US dollars unless otherwise stated):   After-Tax net present value (“NPV”) (using a discount rate of 5%) of $304 million with an After-Tax IRR of 42.8% and Payback Period of 2.6 years (Base Case); 15-year UG mine life with 3-year historical tailings processing recovering a total of 38 million payable silver equivalent ounces (“AgEq”) or 453 thousand gold equivalent ounces (“AuEq”), consisting of 34 million silver ounces and 130 thousand gold ounces; Total Project undiscounted after-tax cash flow of $496 million; Initial capital costs of $83.5 million, including $10.9 million in contingency costs, over an expected 18-month build, and sustaining capital costs of $213 million over the life of mine (“LOM”); The 2026 PEA mine plan is designed as stand-alone to the PFS, with a potential overlap of initial capital cost of $17M (e.g., grid power, offices); Average LOM operating cash costs of $1,351/oz AuEq, and all in sustaining costs (“AISC”) of $2,019/oz AuEq or Average LOM operating cash costs of $16.05/oz AgEq, and AISC of $23.98/oz AgEq; Average annual production of approximately 2.3 million AgEq oz or 27.8 thousand AuEq oz, consisting of 2.1 million silver ounces and 8.0 thousand gold ounces (refer to Table 10 footnotes for conversion to Eq ozs); and PEA Study of the Southern Veins does not include the 38 million ounces AgEq contained in the Northern Veins (see details in updated Mineral Resource Estimate below).   We also go on to unpack all the #exploration upside still at surface, in the underground, and along the district-scale mineralized trend of a number of historic past-producing mines that will have drill programs for many years into the future.   If you have any follow up questions for Glenn regarding Silver Tiger Metals, then please email them into me at Shad@kereport.com.   In full disclosure, Shad is a shareholder of Silver Tiger Metals at the time of this recording, and may choose to buy or sell shares at any time.    Click here to follow the latest news from Silver Tiger Metals   For more market commentary & interview summaries, subscribe to our Substacks:   The KE Report: https://kereport.substack.com/ Shad's resource market commentary: https://excelsiorprosperity.substack.com/     Investment disclaimer: This content is for informational and educational purposes only and does not constitute investment advice, an offer, or a solicitation to buy or sell any security. Investing in equities and commodities involves risk, including the possible loss of principal. Do your own research and consult a licensed financial advisor before making any investment decisions. Guests and hosts may own shares in companies mentioned.      

The Prime Minister says voters shouldn't expect any big election promises this year, as the Government looks to keep the books in order. Chris Luxon's given his State of the Nation speech in Auckland before 600 business leaders. Luxon declared the economic recovery is here, and pointed to Kiwisaver, RMA and education reforms as this year's policy planks. NZ Herald political editor Thomas Coughlan says the Government's dialled back the rhetoric this time round, as part of a 'low risk, low reward' strategy. LISTEN ABOVESee omnystudio.com/listener for privacy information.

This episode of the NGPF podcast features Walter Green, founder of the Say It Now movement, who shares how expressing specific, heartfelt gratitude to people who have impacted our lives can strengthen relationships and create lasting meaning. Walter describes his personal "gratitude journey," including traveling to thank 44 people in person, and explains how that experience inspired a global initiative now reaching tens of thousands of schools worldwide. Yanely and Walter discuss why students and educators often get stuck in short-term stressors, and how intentional reflection and gratitude can help shift mindset, build connection, and support well-being. The conversation offers simple, classroom-friendly ways to bring the practice to students, such as writing letters, recording short messages, or making gratitude more routine without needing a special holiday. They also connect gratitude to life readiness, emphasizing that relationship-building is a key skill that supports long-term success, including financial and professional opportunities. Prospective listeners will leave with practical ideas and inspiring stories that can help students, and teachers, feel more connected, valued, and motivated.

Surro Connections was once a reputable surrogacy agency that operated out of Camas, Washington. The company helped match surrogates with prospective parents and facilitated communication and payments between them. But the agency abruptly closed late last year, leaving clients without access to the tens of thousands of dollars needed to pay the surrogates carrying their children. The whereabouts of the company’s founder, Megan Hall-Greenberg, are unknown. Investigative health care reporter Sarah Kliff talked to clients, surrogates and former employees of Surro Connections for the New York Times. She joins us with more details about the closure and the largely unregulated surrogacy industry in the U.S.

Fear of failure holds more people back from entrepreneurship than anything else, and most don't even realize it. In this episode, I break down how fear shows up in business decisions, how to reframe failure, and what it actually costs you to delay taking action. Whether you're thinking about buying a franchise, starting a business, or expanding one you already own, this episode will shift your mindset and help you identify what's really keeping you stuck. Because at the end of the day, failure isn't something to avoid; it's a necessary step on the path to success.-----------------Considering Investing In A Franchise?

The City of Cortez is holding an information session for residents considering a run for City Council, as nomination deadlines approach for the April election.

#DJChase #ThePreGamepartymixpodcast #PodcastThe Pre-Game Party Mix Podcast The Number #1 Urban PodcastThis week DJ Chase is bigger and better for 2025. Today DJ Chase is back with a special episode. Today DJ Chase is live with A&R Professional and Oklahoma City Artist Scott Da Roc. DJ Chase and Scott Da Roc talk about how she got started in music, becoming an a&r, and as always tips and tricks on how to make it in the new music business. Hope You Guys Enjoy!!!Let's Win! Peace and Blessings! Like, Comment, and Subscribe #DJChaseTV►Follow Scott Da Roc: https://www.instagram.com/official_scottdaroc/Purchase The all New Book From DJ Chase - The Record Label (Cheat Sheet) Vol. 2 - https://a.co/d/6yoxpR6►Follow DJ Chase: https://www.instagram.com/_djchase__/►Connect: https://djchase.net/►Connect: https://www.djchaseradio.com/ WDJC-DB DJ Chase Radio ►Connect: https://www.instagram.com/djchaseradio/►Connect: https://www.facebook.com/DJChaseradio/Download the All New Vocana Music App -https://www.vocana.co/dj-chase►Subscribe to the Pre-Game Party Mix Podcast Thank You for Enjoying This Content

Prospective Perspective – we are looking ahead by looking back. A new year – what may drive returns into 2026. So many guests, so much wisdom as we kick off another great year of the TDI Podcast and a great compilation this week of guest clips from 2025. Learn More at http://www.ibkr.com/funds Follow @andrewhorowitz Looking for style diversification? More information on the TDI Managed Growth Strategy – https://thedisciplinedinvestor.com/blog/tdi-strategy/ Stocks mentioned in this episode: (SPY), (RTX), (NOC), (SHLD), (GLD)

On this New Year's Eve 2025, we take a trip back to visit our origin story, chat about all the things, and look forward to 2026! But, FIRST thank you to all our listeners, guests, friends, clients and family for your support of The Parlour with Lori and Lisa as we celebrate this 100th episode! Thank you, Zoom for making it easy to connect and record our episodes, and Buzzsprout for their user friendly platform for us to post our shows. Books we've read for "The Library: Rebecca Skloot's, "The Immortal Life of Henrietta Lacks"Irene Sardanis', "Out of the Bronx" and "Connections"Scot Loyd's, "The God I Was Given: Looking for Faith After Losing My Religion". And many more! Guests We've Had on the Pod: Check out their episodes, websites and social links!Jim Gardner: https://www.buzzsprout.com/admin/2063865/episodes/12073864-welcome-to-the-parlour-w-a-special-guest-and-morehttps://jimgardnerconstruction.com/Nathan Warner: https://www.buzzsprout.com/admin/2063865/episodes/12351951-shroom-talk-with-nathan-warnerhttps://fresnomycology.org/Mark Feathers: https://www.buzzsprout.com/admin/2063865/episodes/12366255-have-we-got-a-honey-for-youCasey Gardner: https://www.buzzsprout.com/admin/2063865/episodes/12397396-an-american-student-loan-story-part-1https://www.patreon.com/TheSickBitchesPodcastLourin Hubbard: https://www.facebook.com/LourinHubbard/Lourin and Brent joined us here: https://www.buzzsprout.com/admin/2063865/episodes/12677248-the-political-parlour-with-lourin-hubbard-and-brent-hennrichBrent Hennrich: https://brenthennrich.com/Irene Sardanis: https://www.buzzsprout.com/admin/2063865/episodes/12721501-welcome-to-our-first-episode-of-the-library-w-irene-sardanis-phdhttps://www.irenesardanis.com/Jessica Anderson: https://www.buzzsprout.com/admin/2063865/episodes/13767475-into-the-homestretch-with-jessica-anderson-for-virginiahttps://jess4va.com/Gina Thompson McKuen: https://www.buzzsprout.com/admin/2063865/episodes/14118360-welcome-to-the-parlour-ginahttps://www.mahoganysnowcreations.com/shopLorrel Plimier: https://www.buzzsprout.com/admin/2063865/episodes/14301646-welcome-lorrel-plimierhttps://www.lorrelplimier.com/Joanna Basile: https://www.buzzsprout.com/admin/2063865/episodes/14346110-welcome-to-the-bubble-broadcast-joanna-basilehttps://www.unrehearsedwithjb.com/Ruby Jane Castle: https://www.buzzsprout.com/admin/2063865/episodes/14373763-welcome-to-the-parlour-ruby-jane-castleThe Hood Dentist: https://www.buzzsprout.com/admin/2063865/episodes/14541125-welcome-to-the-parlour-the-hood-dentisthttps://www.tiktok.com/@sparkdawgmusic?lang=enScot Loyd: https://www.buzzsprout.com/admin/2063865/episodes/17397070-welcome-to-the-parlour-scot-loydhttps://www.amazon.com/God-Was-Given-Looking-Religion/dp/1964252520Lindsey Ian Cole: https://www.buzzsprout.com/admin/2063865/episodes/17624794-welcome-to-the-parlour-lindsey-ian-colehttps://www.tiktok.com/@lindseyiancolehttps://soundcloud.com/lindseycoleand so many more to come! Catch some of our episodes, including this one, on our Youtube channel: https://www.youtube.com/@RooseveltWarfieldMediaSupport the showThe Parlour with Lori and Lisa comes to you with our takes on current events, politics, human interest stories, all things close to our hearts, and so much MORE! Thank you for following our media journey and be sure to look for us as we roll out in all the social platforms. #SlowMedia

Home price growth is cooling, new reports show. Though homeowners may be struggling to sell at asking price, it is good news for prospective buyers. Especially those who've been waiting on the sidelines for a good deal. But, as with most housing issues, the slowdown is regional. Also in this episode: Auto sales were strong in 2025, Gen Zers see cash in a new light, and an unlikely government funds a U.S.-based GED program for Mexican immigrants.Every story has an economic angle. Want some in your inbox? Subscribe to our daily or weekly newsletter.Marketplace is more than a radio show. Check out our original reporting and financial literacy content at marketplace.org — and consider making an investment in our future.

Home price growth is cooling, new reports show. Though homeowners may be struggling to sell at asking price, it is good news for prospective buyers. Especially those who've been waiting on the sidelines for a good deal. But, as with most housing issues, the slowdown is regional. Also in this episode: Auto sales were strong in 2025, Gen Zers see cash in a new light, and an unlikely government funds a U.S.-based GED program for Mexican immigrants.Every story has an economic angle. Want some in your inbox? Subscribe to our daily or weekly newsletter.Marketplace is more than a radio show. Check out our original reporting and financial literacy content at marketplace.org — and consider making an investment in our future.

Strap in and grab your NG tubes, because the EGS team in TIGER Country is taking you on a fast, forceful, and evidence-packed ride through 15 years of global SBO literature. From the OG 2011 Zielinski model to the latest 2025 predictive tools sweeping across Europe and North America, we're breaking down what matters when the bowel stops behaving and the clock starts ticking.  Join Dr. Rushabh Dev and the Acute Care Surgery crew at the University of Missouri as they tackle the most common EGS consult in America with humor, data, and real-world pearls. Get ready for CT red flags, strangulation scores, Gastrografin truths, and the eternal battle between “operate early” vs. “wait it out.” Whether you're a med student trying to decode your first CT or a seasoned attending debating the next Gastrografin challenge, this episode delivers the insights you need to Dominate the Day. Participants: Dr. Rushabh Dev FACS (Moderator, Surgical Attending) – Assistant Professor of Surgery, Associate PD ACS & SCCM Fellowship, SICU Medical Director, Lieutenant Commander United States Navy Reserve   Dr. Raymond Okeke; Acute Care Surgery & SCCM Fellow  Dr. Eugene Ismailov, General Surgery Resident; PGY 5 Dr. Brycen Ratcliffe, General Surgery Resident; PGY 4 Dr. Desra Flecher, General Surgery Resident; PGY 3 Objectives: 1. Identify the core clinical and CT predictors of operative need in SBO including mesenteric edema, free fluid, closed-loop obstruction, lack of enhancement, and feces sign absence — and understand how these features have remained consistent across 15 years of research. 2. Compare major international SBO predictive models (Zielinski, Geneva Severity Score, STRISK, and NOFA) and describe how they inform real-time decision-making in North American acute care surgery. 3. Apply evidence-based algorithms, including the 2025 JTACS EGS pathway to structure SBO evaluation, integrate Water-Soluble Contrast studies, and avoid delayed surgery in high-risk patients. 4. Evaluate the long-term impact of operative vs. non-operative management with emphasis on recurrence risk, timing between episodes, and how to incorporate recurrence data into patient counseling. 5. Synthesize 15 years of evolving SBO literature into practical bedside strategies by balancing red-flag findings, risk-model guidance, and individualized clinical judgment to optimize outcomes. STRISK and NOFA Calculator: Prediction Models | Clinical Abdominal Surgery Helsinki References  1. Geneva Clinical Severity Score Wassmer, C. H., Guber, J., Zeindler, J., Meier, R. P. H., Ouaïssi, M., Ris, F., Morel, P., Didier, C., & Gkikas, I. (2023). A new clinical severity score for the management of adhesive small bowel obstruction: A cohort study. International Journal of Surgery, 109, 262–270. https://pubmed.ncbi.nlm.nih.gov/37026805/ 2. STRISK & NOFA Predictive Models Räty, S., Rinta-Kilpinen, E., Eklund, M., Turunen, N., Koskinen, I., Rasilainen, S., Korhonen, T., & Paajanen, H. (2025). Development and external validation of prediction risk models for strangulation or non-operative treatment failure in small bowel obstruction: A multicenter prospective study. Surgery, 178(1), 45–56. Prediction Models | Clinical Abdominal Surgery Helsinki 3. JTACS EGS Algorithm – Evidence-Based, Cost-Effective Management Livingston, D. H., Wolfson, D., Cogbill, T. H., Rice, T. W., Patel, N., et al. (2025). Evidence-based, cost-effective management of small bowel obstruction: An Emergency General Surgery Algorithms Work Group project. Journal of Trauma and Acute Care Surgery, 98(4), 512–528. https://pubmed.ncbi.nlm.nih.gov/40842046/ 4. Tennessee Recurrence Study (Operative vs Non-Operative Management) Medvecz, A. J., Dennis, B. M., Wang, L., Countouris, M. E., Croce, M. A., Sharpe, J. P., Ivanova, A., & Miller, R. S. (2020). Impact of operative management on recurrence of adhesive small bowel obstruction: A longitudinal analysis of a statewide database. Journal of the American College of Surgeons, 230(4), 544–551.e1. https://pubmed.ncbi.nlm.nih.gov/31954815/ 5. Early Predictive SBO Work – Zielinski (2010–2011) Zielinski, M. D., Eiken, P. W., Bannon, M. P., Heller, S. F., Lohse, C. M., & Huebner, M. (2010). Small bowel obstruction—Who needs an operation? A multivariate prediction model. World Journal of Surgery, 34(5), 910–919. https://pubmed.ncbi.nlm.nih.gov/20217412/ 6. Zielinski, M. D., Haddad, N. N., Cullinane, D. C., Eiken, P. W., & Huebner, M. (2011). Prospective, observational validation of a multivariate small bowel obstruction model to predict the need for operative intervention. Journal of the American College of Surgeons, 212(6), 1068–1076. https://pubmed.ncbi.nlm.nih.gov/21458305/ Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.   If you liked this episode, check out our recent episodes here: https://behindtheknife.org/listen Behind the Knife Premium: General Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-review Trauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlas Dominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkship Dominate Surgery for APPs: A High-Yield Guide to Your Surgery Rotation: https://behindtheknife.org/premium/dominate-surgery-for-apps-a-high-yield-guide-to-your-surgery-rotation Vascular Surgery Oral Board Review Course: https://behindtheknife.org/premium/vascular-surgery-oral-board-audio-review Colorectal Surgery Oral Board Review Course: https://behindtheknife.org/premium/colorectal-surgery-oral-board-audio-review Surgical Oncology Oral Board Review Course: https://behindtheknife.org/premium/surgical-oncology-oral-board-audio-review Cardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-audio-review Download our App: Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049 Android/Google Play: https://play.google.com/store/apps/details?id=com.btk.app&hl=en_US

Make sure to grab & understand 14 Franchise Buying Mistakes that could destroy your investment: https://www.franchiseempire.com/14fbm?utm_source=TJDec272025Join my list to receive Top Resale Franchises every week: https://www.franchiseempire.com/resalelist?utm_source=TJDec272025

AEM Podcast host Ken Milne, MD, and guest skeptic Lauren Westafer, DO, MPH, MS, interview lead author Zachary Binder, MD. Learn more in the accompanying Hot Off the Press article available in The Skeptics' Guide to Emergency Medicine.

Download our list of 42 High Performing (and profitable) Franchises: https://www.franchiseempire.com/42hpf?utm_source=FEdec142025Most people think they can buy a franchise, hire a GM, and the business will just run itself, but that's rarely how it works. In this episode, we break down the truth about passive and semi-absentee franchise ownership, when it actually works, and why most brands don't allow it out of the gate. You'll learn what franchisors expect from new owners and the mindset shift required if you want real freedom down the line. If you're thinking about investing in a franchise with minimal involvement, this conversation will save you time, money, and frustration.------------------Considering Investing In A Franchise?

Is Your LinkedIn Personal Branding Built for Buyers or Bystanders? "Respectfully, you are not my audience." Performance coach Giselle Ugarte said that on a recent episode of the Sales Gravy Podcast, and it might be the most liberating thing you'll hear about LinkedIn personal branding this year. Because somewhere between building your profile and hitting publish on that post, you've started making decisions based on what your college roommate might think. Or your former boss. Or yes, your mom. The hard truth? None of them are writing you commission checks. The Real Reason Your LinkedIn Personal Branding Falls Flat You've heard "be authentic" and "show up as yourself" so often that the advice has lost all meaning. So you end up in a strange middle ground where you're not polished enough to impress executives and not human enough to connect with actual buyers. Your LinkedIn personal branding suffers because you're creating content for ghosts. People who will never hire you, never refer you, never sign a contract. You're worried about the wrong audience, and that hesitation shows up in every word you type. Think about the last post you almost published but didn't. What stopped you? Probably not a legitimate business concern. More likely, you had a flash of "what will people think?" and that voice didn't belong to your ideal client. It belonged to someone in your network who wouldn't buy from you if you were the last salesperson on earth. Who Your LinkedIn Content Is Really For Your LinkedIn personal branding should speak to three groups:  Current clients  Prospective clients  People who can refer you to clients That's it. Everyone else is background noise. When you post about closing a tough deal, your brother who works in IT might think you're bragging. Your client, who fought through the same challenge, is nodding in agreement. When you share a lesson from a deal that went sideways, your high school friend might wonder why you're airing dirty laundry. Your prospect is realizing you understand their world. The disconnect happens because you're trying to serve two masters. You want to build real relationships with buyers while also maintaining some imaginary professional image for people who have zero impact on your business. The Transform 20: LinkedIn Personal Branding That Actually Works If you're going to shift your LinkedIn personal branding from performative to productive, you need a system. Not another "post three times a week" generic advice pile, but something that forces you to focus on real humans instead of vanity metrics. Giselle's practical framework, Transform 20, breaks down into four daily actions, each designed to build actual relationships: Connect with 5 new people. Not random connections. People you met this week, people on your calendar, people who recognize your face. Every request should feel familiar to them. Send 5 meaningful messages. Check in. Reference something personal. End with a question. “Let me know” is where leads go to die. Meaningful DMs teach the algorithm who matters to you — and who should see your content. Leave 5 meaningful comments. Two to three sentences. Add context. Reintroduce yourself if needed. A thoughtful comment builds more trust than another like or emoji ever will. Record 5 one-to-one videos. Sixty seconds or less. “Hey, I was thinking about you because…” It's a pattern interrupt in an inbox full of text and one of the fastest ways to stand out. This is where confidence compounds. Twenty actions. Most people won't do it because it feels like work. But if you woke up to 20 qualified leads tomorrow, would that change your business? That's what you're building here. What Your LinkedIn Profile Should Actually Show Buyers want to know you're a real person. That you have a family, hobbies, interests, failures, and lessons. That you care about something besides your quota. If you blur your Zoom background because you think it's more professional, you're missing an opportunity. Let them see the bookshelf, the Peloton, the framed photo. These details give people something to ask about and a reason to remember you. The same goes for your LinkedIn headline. Yes, include your title. But also include the detail that creates connection. "Mom of four," or "Proud Michigan alum," or whatever matters to you and might matter to them. Make it easier for people to find common ground with you. Stop Creating Content for People Who Will Never Buy You already know who matters: current clients, prospective clients, and people who can refer you to clients. Your former colleague who always has something snarky to say about your posts? They've never sent you a referral. Your friend from college who thinks sales is beneath them? They're not signing contracts. Your family member who wants you to be more buttoned up? They're not in your market. Have the clarity to know that you can't build an effective LinkedIn personal branding presence while trying to please everyone. You'll end up pleasing no one, least of all the people who could actually benefit from working with you. You cannot build effective LinkedIn personal branding while trying to please people who don't impact your business. Before you write that post or record that video, remind yourself: someone would be lucky to hear from me today. You have something valuable to offer — and the courage to show up as a real human. The salespeople winning on LinkedIn aren't the most polished. They're the most human. They make it easier for the right people to decide they want to work with them. Send the videos. Start the conversations. Show up as the person your clients actually want to buy from. That's how you win on LinkedIn — and everywhere else. Want the full LinkedIn playbook? Buy The LinkedIn Edge by Jeb Blount and Brynne Tillman. It's packed with non-negotiables that will turn your profile into a pipeline-building machine.

Is Your LinkedIn Personal Branding Built for Buyers or Bystanders? "Respectfully, you are not my audience." Performance coach Giselle Ugarte said that on a recent episode of the Sales Gravy Podcast, and it might be the most liberating thing you'll hear about LinkedIn personal branding this year. Because somewhere between building your profile and hitting publish on that post, you've started making decisions based on what your college roommate might think. Or your former boss. Or yes, your mom. The hard truth? None of them are writing you commission checks. The Real Reason Your LinkedIn Personal Branding Falls Flat You've heard "be authentic" and "show up as yourself" so often that the advice has lost all meaning. So you end up in a strange middle ground where you're not polished enough to impress executives and not human enough to connect with actual buyers. Your LinkedIn personal branding suffers because you're creating content for ghosts. People who will never hire you, never refer you, never sign a contract. You're worried about the wrong audience, and that hesitation shows up in every word you type. Think about the last post you almost published but didn't. What stopped you? Probably not a legitimate business concern. More likely, you had a flash of "what will people think?" and that voice didn't belong to your ideal client. It belonged to someone in your network who wouldn't buy from you if you were the last salesperson on earth. Who Your LinkedIn Content Is Really For Your LinkedIn personal branding should speak to three groups:  Current clients  Prospective clients  People who can refer you to clients That's it. Everyone else is background noise. When you post about closing a tough deal, your brother who works in IT might think you're bragging. Your client, who fought through the same challenge, is nodding in agreement. When you share a lesson from a deal that went sideways, your high school friend might wonder why you're airing dirty laundry. Your prospect is realizing you understand their world. The disconnect happens because you're trying to serve two masters. You want to build real relationships with buyers while also maintaining some imaginary professional image for people who have zero impact on your business. The Transform 20: LinkedIn Personal Branding That Actually Works If you're going to shift your LinkedIn personal branding from performative to productive, you need a system. Not another "post three times a week" generic advice pile, but something that forces you to focus on real humans instead of vanity metrics. Giselle's practical framework, Transform 20, breaks down into four daily actions, each designed to build actual relationships: Connect with 5 new people. Not random connections. People you met this week, people on your calendar, people who recognize your face. Every request should feel familiar to them. Send 5 meaningful messages. Check in. Reference something personal. End with a question. “Let me know” is where leads go to die. Meaningful DMs teach the algorithm who matters to you — and who should see your content. Leave 5 meaningful comments. Two to three sentences. Add context. Reintroduce yourself if needed. A thoughtful comment builds more trust than another like or emoji ever will. Record 5 one-to-one videos. Sixty seconds or less. “Hey, I was thinking about you because…” It's a pattern interrupt in an inbox full of text and one of the fastest ways to stand out. This is where confidence compounds. Twenty actions. Most people won't do it because it feels like work. But if you woke up to 20 qualified leads tomorrow, would that change your business? That's what you're building here. What Your LinkedIn Profile Should Actually Show Buyers want to know you're a real person. That you have a family, hobbies, interests, failures, and lessons. That you care about something besides your quota. If you blur your Zoom background because you think it's more professional, you're missing an opportunity. Let them see the bookshelf, the Peloton, the framed photo. These details give people something to ask about and a reason to remember you. The same goes for your LinkedIn headline. Yes, include your title. But also include the detail that creates connection. "Mom of four," or "Proud Michigan alum," or whatever matters to you and might matter to them. Make it easier for people to find common ground with you. Stop Creating Content for People Who Will Never Buy You already know who matters: current clients, prospective clients, and people who can refer you to clients. Your former colleague who always has something snarky to say about your posts? They've never sent you a referral. Your friend from college who thinks sales is beneath them? They're not signing contracts. Your family member who wants you to be more buttoned up? They're not in your market. Have the clarity to know that you can't build an effective LinkedIn personal branding presence while trying to please everyone. You'll end up pleasing no one, least of all the people who could actually benefit from working with you. You cannot build effective LinkedIn personal branding while trying to please people who don't impact your business. Before you write that post or record that video, remind yourself: someone would be lucky to hear from me today. You have something valuable to offer — and the courage to show up as a real human. The salespeople winning on LinkedIn aren't the most polished. They're the most human. They make it easier for the right people to decide they want to work with them. Send the videos. Start the conversations. Show up as the person your clients actually want to buy from. That's how you win on LinkedIn — and everywhere else. Want the full LinkedIn playbook? Buy The LinkedIn Edge by Jeb Blount and Brynne Tillman. It's packed with non-negotiables that will turn your profile into a pipeline-building machine.

ALSO: Indiana Senate to vote on new congressional map, Indianapolis teen killed in Kentucky State University shooting, Fed cuts rates again, and IU Football QB & Coach honored again.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

 Fertility Docs Uncensored is hosted by Dr. Carrie Bedient from the Fertility Center of Las Vegas, Dr. Susan Hudson from Texas Fertility Center, and Dr. Abby Eblen from Nashville Fertility Center. Today we welcome special guest Lauren Makler, Founder of Cofertility. In this episode of Fertility Docs Uncensored, the doctors sit down with Lauren Makler to explore why transparency is essential in modern egg donation. For years, donor conception carried an unnecessary layer of secrecy. Parents often felt shame discussing the use of an egg donor, and donor-conceived children sometimes internalized guilt or discomfort, feeling that the process was transactional, or that the donor was excluded from any meaningful connection. Lauren explains how the Cofertility model aims to reshape this narrative entirely. Prospective egg donors undergo extensive medical and psychological screening before being accepted. Those who qualify complete an extraordinarily detailed profile allowing families to choose a donor whose values, background, and goals align with theirs. The donor is empowered too since she keeps half of her eggs for future use. Only a limited number of families can match with each donor, and together, donors and recipient families determine their preferred level of ongoing contact. At minimum, recipients receive identifying information, but many matches opt for deeper communication, shared updates, or even in-person meetings over time. This thoughtful, relationship-centered approach helps ensure that donor-conceived children grow up with honesty, openness, and pride in their origin story. Transparency removes shame, strengthens family identity, and honors the donor's contribution in a meaningful, human way. At its core, every child's conception however it happens, should be embraced with joy, not secrecy. This podcast was sponsored by Cofertility. 

The Three Archetypes of American Global Strategy — Gaius & Germanicus — Gaius and Germanicus analyze the prospective American National Security Strategy for 2025–2026, framing it as a deliberate return to the "Trump corollary" of the Monroe Doctrine emphasizing hemispheric supremacy and regional sphere-of-influence arrangements. Germanicus categorizes American foreign policy history into three religious-like ideological visions: Washington'sisolationist "beacon on the hill," the Monroe-Adams "realm of liberty" (defensive empire protecting American interests), and the Jacksonian "Prometheus unbound" (universalist ideological expansion spreading democratic values). Germanicus argues the incoming administration systematically rejects the "Wilson to Biden" lineage of global interventionism and messianic crusading in favor of Theodore Roosevelt-style "flexible realism" emphasizing power, national interest, and transactional diplomacy. Gaius details this shifted strategy as consolidating American dominance in the Western Hemisphere and Pacific region while according Russia respect and a recognized sphere of influence in Eurasia, explicitly rejecting Cold War confrontationalism. Gaius documents that Kremlin leadership has explicitly welcomed this "flexible realism," viewing it as a geopolitical departure from perpetual adversarial Cold War mindset. Germanicus contrasts this transactional approach with the "Manichaean" moral crusades characterizing recent American foreign policy, suggesting the American public now explicitly favors strategy avoiding military entanglement while prioritizing domestic prosperity and economic reconstruction, mirroring isolationist sentiments following World War I. 1911 USS MAINE IN HAVANA HARBOR

In this episode, the CardioNerds (Dr. Naima Maqsood, Dr. Akiva Rosenzveig, and Dr. Colin Blumenthal) are joined by renowned educator in electrophysiology, Dr. Joshua Cooper, to discuss everything atrial flutter; from anatomy and pathophysiology to diagnosis and management. Dr. Cooper's expert teaching comes through as Dr. Cooper vividly describes atrial anatomy to provide the foundational understanding to be able to understand why management of atrial flutter is unique from atrial fibrillation despite their every intertwined relationship. A foundational episode for learners to understand atrial flutter as well as numerous concepts in electrophysiology. Audio editing for this episode was performed by CardioNerds intern Dr. Bhavya Shah.  CardioNerds Atrial Fibrillation PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Pearls "The biggest mistake is failure to diagnose”. Atrial flutter, especially with 2:1 conduction, is commonly missed in both inpatient and outpatient settings so look carefully at that 12-lead EKG so you can mitigate the stroke and tachycardia induced cardiomyopathy risk  Decremental conduction of the AV node makes it more challenging to rate control atrial flutter than atrial fibrillation  Catheter Ablation is the first line treatment for atrial flutter and is highly successful, but cardioversion can be utilized as well prior to pursuing ablation in some cases.  Class I AADs like propafenone and flecainide may stability the atrial flutter circuit by slowing conduction and thus may worsen the arrhythmia. Therefore, the preferred anti-arrhythmic medication in atrial flutter are class III agents.  Atrial flutter can be triggered by firing from the left side of the heart, so in patients with both atrial fibrillation and flutter, ablating atrial fibrillation makes atrial flutter less likely to recur.  BONUS PEARL: Dr. Cooper's youtube video on atrial flutter is a MUST SEE!  Notes Notes: Notes drafted by Dr. Akiva Rosenzveig  What are the distinguishing features of atrial fibrillation and flutter?  Atrial flutter is an organized rhythm characterized by a wavefront that continuously travels around the same circuit leading to reproducible P-waves on surface EKG as well as a very mathematical and predictable relationship between atrial and ventricular activity  Atrial fibrillation is an ever changing, chaotic rhythm that consists of small local circuits that interplay off each other. Consequently, no two beats are the same and the relationship between the atrial activity and ventricular activity is unpredictable leading to an irregularly irregular rhythm  What are common atrial flutter circuits?  Cavo-tricuspid isthmus (CTI)-dependent atrial flutter is the most common type of flutter. It is characterized by a circuit that circumnavigates the tricuspid valve.  Typical atrial flutter is characterized by the circuit running in a counterclockwise pattern up the septum, from medial to lateral across the right atrial roof, down the lateral wall, and back towards the septum across the floor of the right atrium between the IVC and the inferior margin of the tricuspid valve i.e. the cavo-tricuspid isthmus. Surface EKG will show a gradual downslope in leads II, III, and AvF and a rapid rise at end of each flutter wave.   Atypical CTI-dependent flutter follows the same route but in the opposite direction (clockwise). Therefore, we will see positive flutter waves in the inferior leads   Mitral annular flutter is more commonly seen in atrial fibrillation patients who've been treated with ablation leading to scarring in the left atrium.  Roof-dependent flutter is characterized by a circuit that travels around left atrium circumnavigating a lesion (often from prior ablation), traveling through the left atrial roof, down the posterior wall, and around the pulmonary veins  Surgical/scar/incisional flutter is seen in people with a history of prior cardiac surgery and have iatrogenic scars in right atrium due to cannulation sites or incisions  How does atrial flutter pharmacologic management differ from other atrial arrhythmias?  The atrioventricular (AV) node is unique in that the faster it is stimulated, the longer the refractory period and the slower it conducts. This characteristic is called decremental conduction. In atrial fibrillation, the atrial rate is so fast that the AV node becomes overwhelmed and only lets some of those signals through to the ventricles creating an irregular tachycardia but at lower rates. In atrial flutter, the atrial rate is slower, therefore the AV node has more capability to conduct allowing for higher ventricular rates. Therefore, to achieve rate control one will need a higher dose of AV blocking medications. Atrial tachycardia may require even higher doses due to the increased ability of the AV node to conduct, as the atrial rates are slower than in atrial flutter.  Sodium channel blockers (Class I) such as flecainide and propafenone slow wavefront propagation, making it easier for the AV node to handle the atrial rates. This will end up leading to increased ventricular rates which can be dangerously fast. That is why AV nodal blockers should be used in conjunction with flecainide and propafenone.  What is the role of cardioversion in atrial flutter management?  Due to high success rate with atrial flutter ablation, ablation is the first line treatment. However, sometimes cardioversion may be utilized in patients depending on how symptomatic they are and how long it will take to get an ablation. Cardioversion may also be utilized preferentially when the atrial flutter was triggered by infection or cardiac surgery to see if it will come back.   If cardioversion is pursued, the patient will need to be anticoagulated due to the stroke risk after the procedure due to post-conversion stunning.  How effective is atrial flutter ablation?  The landmark Natale et al study in 2000 demonstrated 80% success rate after radiofrequency ablation as compared to 36% in patients on anti-arrhythmic therapy. The LADIP study in 2006 further corroborated these findings. Contemporary data shows above 90% success rate of atrial flutter ablation.  In patients who have had both atrial fibrillation and atrial flutter, most electrophysiologists would ablate both. However, in patients with atrial fibrillation, the atrial flutter usually is initiated by trigger spots firing in the left atrium. Once the atrial fibrillation is ablated, the flutter will become less likely. Therefore, there are those who say there's no need to ablate the flutter circuit as well. Alternatively, if a patient has severe comorbidities and/or is high risk for ablation, one may consider performing the atrial flutter ablation only since atrial flutter is harder to manage medically compared with atrial fibrillation.   How do you manage atrial flutter in the acute inpatient setting?  In the inpatient setting, electrical cardioversion is often limited by blood pressure and the hypotensive effects of the sedatives required. If one is awake and too hypotensive, chemical cardioversion can be pursued. The most effective anti-arrhythmic for this is ibutilide. Amiodarone is not effective for acute cardioversion. Since ibutilide prolongs refractoriness in atrial and ventricular tissue, there's a risk of long QT induced torsades de pointes. Pretreating with magneisum reduces the risk to 1-2%.  References Jolly WA, Ritchie WT. Auricular flutter and fibrillation. 1911. Ann Noninvasive Electrocardiol. 2003;8(1):92-96. doi:10.1046/j.1542-474x.2003.08114.x  McMichael J. History of atrial fibrillation 1628-1819 Harvey - de Senac - Laënnec. Br Heart J. 1982;48(3):193-197. doi:10.1136/hrt.48.3.193  Lee KW, Yang Y, Scheinman MM; University of Califoirnia-San Francisco, San Francisco, CA, USA. Atrial flutter: a review of its history, mechanisms, clinical features, and current therapy. Curr Probl Cardiol. 2005;30(3):121-167. doi:10.1016/j.cpcardiol.200  2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2024;149(1):e167. doi:10.1161/  Cosío F. G. (2017). Atrial Flutter, Typical and Atypical: A Review. Arrhythmia & electrophysiology review, 6(2), 55–62. https://doi.org/10.15420/aer.2017.5.2  https://www.escardio.org/Journals/E-Journal-of-Cardiology-Practice/Volume-11/Atrial-flutter-common-and-main-atypical-forms Natale A, Newby KH, Pisanó E, et al. Prospective randomized comparison of antiarrhythmic therapy versus first-line radiofrequency ablation in patients with atrial flutter. J Am Coll Cardiol. 2000;35(7):1898-1904. doi:10.1016/s0735-1097(00)00635-5  Da Costa A, Thévenin J, Roche F, et al. Results from the Loire-Ardèche-Drôme-Isère-Puy-de-Dôme (LADIP) trial on atrial flutter, a multicentric prospective randomized study comparing amiodarone and radiofrequency ablation after the first episode of symptomatic atrial flutter. Circulation. 2006;114(16):1676-1681. doi:10.1161/CIRCULATIONAHA.106.638395  https://www.acc.org/Membership/Sections-and-Councils/Fellows-in-Training-Section/Section-Updates/2015/12/15/16/58/Atrial-Fibrillation#:~:text=The%20first%20'modern%20day'%20account,in%20open%20chest%20animal%20models.&text=In%201775%2C%20William%20Withering%20first,(purple%20foxglove)%20in%20AFib.

Grab our breakdown of the 5 Low-Cost Businesses That Make $1 Million: https://www.franchiseempire.com/lowcost?utm_source=FENov302025Also, if you liked this video, but don't think the food industry is for you, check out this tool shop business breakdown: https://youtu.be/5jqCWyUq8ccIf you liked this video, but think a food franchise is too expensive, check out this video to find a better opportunity for you: Ever wondered how much money McDonald's franchise owners actually make? In this video, we reveal what it really costs to open a McDonald's, how much franchisees are paying in royalties and rent, and the surprising way McDonald's makes most of its money (hint: it's not burgers). We'll also break down how their average $4M revenue stacks up against other fast food giants and whether owning one is worth the $2 million+ investment.If you're considering investing in a fast food franchise or exploring business opportunities with big potential, this one's a must-watch.------------------Considering Investing In A Franchise?

In this episode, I'm sharing the exact tough-love truth I give my one-on-one clients inside Play Cafe Academy and Playmaker Society—the things I say privately that genuinely help people avoid incredibly expensive, stressful, and sometimes irreversible mistakes when opening an indoor playground or play café.This audio is pulled directly from a YouTube video I recently published, and I wanted to share it here because it's that important. But if you want to make sure you never miss content that doesn't make it over to the podcast feed, be sure to subscribe to my YouTube channel as well.If you're in the planning phase, this is the reality check you need before signing a lease, building a business plan, launching a GoFundMe, choosing a location, or assuming open play alone will carry your business. I walk through the most common misconceptions I see every week—unrealistic revenue projections, relying too heavily on vendors, expecting your customers to be loyal, thinking you can bring your kids to work, underestimating the impact on your relationship, and more.I'm also diving into why no one wants to fund your dream, how crowdfunding can work when used as a marketing strategy (not a funding plan), and why your startup budget, projected revenue, and marketing spend need to align if you want the business to be sustainable and your life to stay intact.My intention isn't to scare you—it's to give you the full, unfiltered picture so you can move forward with clarity, confidence, and realistic expectations. A play café can absolutely be profitable and joyful, but only if it's built on truth, not wishful thinking.If you enjoyed this episode and want a part two for current owners, send me a message or leave a review.RESOURCES MENTIONED:Business Plan ToolkitWhy You Can't Bring Your Kids To Work What Opening an Indoor Playground CostsOTHER RESOURCES:Play Cafe Academy & Play Makers SocietyGetting Started With Your Play Cafe [YouTube Video Playlist]What's Working In The Indoor Play Industry 2025 GuideFund Your Indoor Play Business [Free Training]Indoor Play Courses & 1:1 Consulting WaitlistMichele's InstagramMichele's WebsitePlay Cafe Academy YouTube ChannelETSY Template ShopPrepare Your Indoor Playground For a RecessionPlay Cafe Academy & Play Makers SocietyQuestions and Support: Support@michelecaruana.com Play Cafe Academy & Play Makers Society: http://bit.ly/3HES7fDQuestions and Support: Support@michelecaruana.com Simplify and Scale with 50% OFF WellnessLiving: https://discover.wellnessliving.com/playcafeacademyActive Campaign Free Trial: https://www.activecampaign.com/?_r=D6IYK3HG

Download our list of 42 High Performing (and profitable) Franchises: https://www.franchiseempire.com/42hpf?utm_source=TJnov252025If you like this video and want to learn how to fund your business, check out this video: https://youtu.be/VQhnGLuHDTsThinking about buying a franchise in 2025? Wondering if you can keep your job and still make passive income from a semi-absentee franchise? In this video, we reveal the hard truth about passive franchise ownership and break down the biggest mistakes people make when choosing a franchise business model. You'll also learn the pros and cons of brick & mortar vs. service-based franchise opportunities and what works best for first-time buyers. Whether you're researching the best franchises to own or comparing business ideas that make real money, this episode will help you avoid costly errors and choose the right path.------------------Considering Investing In A Franchise?

Today, I'm joined by Gina Cotner, founder and CEO of Athena Executive Services. Gina shares her journey from executive assistant to building one of the top virtual assistant firms in the country. We talk about how to create real accountability on your team, delegate effectively, and build a business that doesn't depend on you doing everything yourself. Gina gives practical, no-fluff advice on managing both remote and in-office teams while keeping productivity and trust high. If you're ready to lead better and free yourself from burnout, this episode is a must-listen.   What you'll hear in this episode: [02:25] Gina's Journey: From Executive Assistant to CEO [03:00] The Importance of Delegation in Business Growth [06:55] Overcoming Barriers to Effective Delegation [19:45] The Role of Accountability in Team Management [27:50] Setting Expectations and Accountability [30:05] Leveraging Resources to Meet Deadlines [33:15] Building a Culture of Accountability [37:15] Effective Communication and Trust [40:20] Hiring and Vetting for Cultural Fit [49:30] Remote Management Best Practices   If you like this episode, check out: Think Bigger Than a Niche Your Most Expensive Habit Why Enterprise Value is the Goal   LinkedIn: Gina Cotner Website: https://www.athenaexecutiveservices.com Prospective clients are encouraged to schedule a conversation with Jennifer Tracy from Athena Executive Services to explore what kind of VA support best fits their business   Learn more about our CFO firm and services: https://www.keepwhatyouearn.com/   Connect with Shannon: https://www.linkedin.com/in/shannonweinstein Watch full episodes: https://www.youtube.com/channel/UCMlIuZsrllp1Uc_MlhriLvQ Follow along on IG: https://www.instagram.com/shannonkweinstein/   The information contained in this podcast is intended for educational purposes only and is not individual tax advice. We love enthusiastic action, but please consult a qualified professional before implementing anything you learn.

This OG of directly contracted high-value networks or Centers of Excellence networks came up, name dropped and everything in the episode with Elizabeth Mitchell from PBGH, the Purchaser Business Group on Health, from two weeks ago. That was episode 491. So, welcome to this deep cut episode with Olivia Ross from way back, pre-pandemic times. This episode of Relentless Health Value revisits the concept of directly contracted high value networks or Centers of Excellence (ECEN) with Olivia Ross. The discussion explores the impact and potential of the ECEN network, emphasizing the importance of quality, price transparency, and multidisciplinary approaches in healthcare.  Olivia delves into the reasons why ECEN was significant in past PBGH projects and its current relevance, despite its eventual dismantling due to corporate changes. The episode highlights the benefits for employers in creating their own high-value networks and the positive outcomes from fewer unnecessary surgeries and better quality care. Additionally, it covers the rigorous process of selecting Centers of Excellence and how continuous quality improvement efforts benefit both employers and healthcare providers. === LINKS ===

A new prospective multicenter cohort of 250 patients with shock examines the safety and outcomes of peripheral vasopressor administration. Extravasation events were rare and clustered only after several days of infusion, while norepinephrine use and simple physiologic markers correlated with survival. In this episode, I translate the findings into bedside guardrails—which sites and gauges to use, how to monitor, and when to pivot to a central line.The Vasopressor & Inotrope HandbookAmazon: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://amzn.to/47qJZe1⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ (Affiliate Link)My Store: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://eddyjoemd.myshopify.com/products/the-vasopressor-inotrope-handbook⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ (Use "podcast" to save 10%)Citation:Petros A, Melkie A, Kotiso KS, Kebede D, Oljira CF, Assefa Gemechu F, Yusuf H, Abebe S, Ashagre A, Bekele A, Yohannes A, Etesa EK, Bedru M, Gebremariam TH. Peripheral line for vasopressor administration: Prospective multicenter observational cohort study for survival and safety. PLoS One. 2025 Oct 13;20(10):e0333275. doi: 10.1371/journal.pone.0333275. PMID: 41082535; PMCID: PMC12517475.

In this Meaningful People episode, financial advisor Moshe Alpert and community advocate Shmuly Hartstein unpack why many frum “middle‑class” families earning $200–300K still feel underwater—tuition that rivals a salary, yom tov and camp costs, seminary and simcha expectations, and the quiet creep of credit‑card debt. They debate income‑based tuition and communal funding versus personal responsibility, and share practical moves: make a real plan, build a budget, ask for a raise or start a side hustle, prioritize local schools in tzedakah, consider lower‑cost simchas or out‑of‑town living, and protect your family with insurance and a will. A candid, solutions‑oriented conversation about money, values, and making frum life sustainable. Moshe Alpert is a Financial Advisor at Ceremian Financial and author of the book ‘Frum Financial Planning: The Easy-to-Read Money Guide for the Orthodox Jewish Community'. https://a.co/d/hsRZrEe and Ceremian.com    Shmuel Hartstein is the founder of Bsefer Chayim, an organization that promotes signing up for Life Insurance in our community. https://www.bseferchayim.org/  This episode was made possible thanks to our sponsors: ►Blooms Kosher   Bring you the best Kosher products worldwide.   https://bloomskosher.com   ______________________________________ ► Colel Chabad Pushka App - The easiest way to give Tzedaka    https://pushka.cc/meaningful    _______________________________________ ► Dream Raffle Win a brand new and fully furnished $1,200,000 apartment in Yerushalayim!    Use Promo code MPP for $10 off and to receive double tickets!   https://thedreamraffle.com/  _____________________________________ ► Lalechet     We're a team of kosher travel experts, here to carry you off to your dream destination swiftly, safely, and seamlessly in an experience you will forever cherish.    https://www.lalechet.com ___________________________________________ ► Town Appliance - Visit the website or message them on WhatsApp     https://www.townappliance.com     https://bit.ly/Townappliance_whatsapp    ______________________________________ ► Touro   Lander College for Men/Beis Medrash L'Talmud offers a unique blend of rigorous Torah study and strong academics, providing students with both spiritual growth and professional preparation. With devoted rebbeim, supportive faculty, and access to Touro's graduate and professional programs, students can pursue over 20 majors and pre-professional tracks — including medicine, law, business, and technology — while maintaining their Jewish values. Highlights include the Medical Honors Pathway with New York Medical College, personalized support services, and an exceptional record of graduate school acceptances. Prospective students are invited to attend the Open House on November 9 to learn more. Visit http://www.lcm.touro.edu/openhouse    ______________________________________ ►  Ketubah - Free Shipping with Code MPP25! At Ketubah.com, every Kesubah is designed with care, blending timeless beauty with texts that are fully halachic, including RCA and Sephardic versions. Our team collaborates with rabbanim and mesadrei kiddushin to ensure each document is accurate and accepted without question. Choosing Ketubah.com means you arrive at your chuppah with peace of mind, knowing your Kesubah is both beautifully crafted and halachically sound. Use code MPP25 for free shipping! https://ketubah.com/meaningful-minutes/?utm_source=Podcast&utm_medium=Clickthrough&utm_campaign=meaningful-people-podcast ______________________________________ ►  Eishet Chayil Eishet Chayil — The Woman of Valor is a new book by Rabbi Yossi Marcus that brings King Solomon's classic poem to life through the stories of 24 remarkable Jewish women — from Sarah and Miriam to Esther and beyond. Drawing on millennia of Jewish scholarship, especially the teachings of the Lubavitcher Rebbe, the book celebrates women of faith, courage, and wisdom. Each verse is paired with contemporary artwork by Israeli artist Lia Baratz, making the book both educational and inspirational for readers of all ages. Dedicated to the women of Nahal Oz who were killed on October 7, 2023, it stands as a tribute to Jewish women of valor throughout history. Already in its second printing, Eishet Chayil is an ideal gift for Bat Mitzvahs, brides, wives, and mothers. Available at https://www.eishetchayil.com and https://store.kehotonline.com/mobile/ Use code MM20 for 20% off when checking out on Kehot.com.

In this heartfelt and eye-opening conversation, veteran shadchan Adina Reich traces the evolution of the shidduch system — from handwritten index cards to WhatsApp chats — and reflects on the hopes, heartbreak, and faith that define it. She opens up about the challenges singles and parents face, the emotional toll on shadchanim, and her groundbreaking new initiative, The Shidduch Lounge, designed to bring back organic, Torah-centered connections. With humor, honesty, and compassion, Adina offers both an insider's view of the shidduch world and a vision for how it can heal. This episode was made possible thanks to our sponsors: ►Blooms Kosher   Bring you the best Kosher products worldwide.   https://bloomskosher.com   ______________________________________ ► Colel Chabad Pushka App - The easiest way to give Tzedaka    https://pushka.cc/meaningful    _______________________________________ ► Dream Raffle Win a brand new and fully furnished $1,200,000 apartment in Yerushalayim!    Use Promo code MPP for $10 off and to receive double tickets!   https://thedreamraffle.com/  _____________________________________ ► Lalechet     We're a team of kosher travel experts, here to carry you off to your dream destination swiftly, safely, and seamlessly in an experience you will forever cherish.    https://www.lalechet.com ___________________________________________ ► Town Appliance - Visit the website or message them on WhatsApp     https://www.townappliance.com     https://bit.ly/Townappliance_whatsapp    ______________________________________ ► Touro   Lander College for Men/Beis Medrash L'Talmud offers a unique blend of rigorous Torah study and strong academics, providing students with both spiritual growth and professional preparation. With devoted rebbeim, supportive faculty, and access to Touro's graduate and professional programs, students can pursue over 20 majors and pre-professional tracks — including medicine, law, business, and technology — while maintaining their Jewish values. Highlights include the Medical Honors Pathway with New York Medical College, personalized support services, and an exceptional record of graduate school acceptances. Prospective students are invited to attend the Open House on November 9 to learn more. Visit http://www.lcm.touro.edu/openhouse    ______________________________________ ►  Ketubah At Ketubah.com, every Kesubah is designed with care, blending timeless beauty with texts that are fully halachic, including RCA and Sephardic versions. Our team collaborates with rabbanim and mesadrei kiddushin to ensure each document is accurate and accepted without question. Choosing Ketubah.com means you arrive at your chuppah with peace of mind, knowing your Kesubah is both beautifully crafted and halachically sound. https://ketubah.com/meaningful-minutes/?utm_source=Podcast&utm_medium=Clickthrough&utm_campaign=meaningful-people-podcast ______________________________________ ►  Eishet Chayil Eishet Chayil — The Woman of Valor is a new book by Rabbi Yossi Marcus that brings King Solomon's classic poem to life through the stories of 24 remarkable Jewish women — from Sarah and Miriam to Esther and beyond. Drawing on millennia of Jewish scholarship, especially the teachings of the Lubavitcher Rebbe, the book celebrates women of faith, courage, and wisdom. Each verse is paired with contemporary artwork by Israeli artist Lia Baratz, making the book both educational and inspirational for readers of all ages. Dedicated to the women of Nahal Oz who were killed on October 7, 2023, it stands as a tribute to Jewish women of valor throughout history. Already in its second printing, Eishet Chayil is an ideal gift for Bat Mitzvahs, brides, wives, and mothers. Available at https://www.eishetchayil.com and https://store.kehotonline.com/mobile/ Use code MM20 for 20% off when checking out on Kehot.com.